Upregulation of the TGFβ signalling pathway by Bcr-Abl: Implications for haemopoietic cell growth and chronic myeloid leukaemia

FEBS Letters

Volumn 581, Issue 7, 2007, Pages 1329-1334

  Møller, Gigi M O ^a   Frost, Victoria ^a   Melo, Junia V ^b   Chantry, Andrew ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Bcr Abl; Leukaemia; Smad; TGF

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; BCR ABL PROTEIN; CD34 ANTIGEN; GENE PRODUCT; IMATINIB; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRIMIDINE DERIVATIVE; SMAD2 PROTEIN; SMAD3 PROTEIN; TGF BETA RECEPTOR PROTEIN KINASE; TGF-BETA RECEPTOR PROTEIN KINASE; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CANCER PATIENT; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL SUBPOPULATION; CELL TRANSFORMATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UPREGULATION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HEMATOPOIETIC STEM CELL; METABOLISM; PLASMID;

ANTIGENS, CD34; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PLASMIDS; PROMOTER REGIONS (GENETICS); PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRIMIDINES; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 33947511855     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2007.02.048     Document Type: Article

References (27)

1. Kim S.J., and Letterio J. Transforming growth factor-β signalling in normal and malignant hematopoiesis. Leukemia 17 (2003) 1731-1737
2. Fortunel N.O., Hatzfeld J.A., Monier M.N., and Hatzfeld A. Control of hematopoietic stem/progenitor cell fate by transforming growth factor-beta. Oncol. Res. 13 (2003) 445-453
3. Hatzfeld J., Li M.L., Brown E.L., Sookdeo H., Levesque J.P., O'Toole T., Gurney C., Clark S.C., and Hatzfeld A. Release of early human hematopoietic progenitors from quiescence by antisense transforming growth factor beta 1 or Rb oligonucleotides. J. Exp. Med. 174 (1991) 925-929
4. Massague J., Seoane J., and Wotton D. Smad transcription factors. Genes Dev. 19 (2005) 2783-2810
5. Buchdunger E., Zimmermann J., Mett H., Meyer T., Muller M., Druker B.J., and Lydon N.B. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56 (1996) 100-104
6. Copland M., Fraser A.R., Harrison S.J., and Holyoake T.L. Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia. Cancer Immunol. Immunother. 54 (2005) 297-306
7. Salesse S., and Verfaillie C.M. BCR/ABL: from molecular mechanisms of leukaemia induction to treatment of chronic myelogenous leukaemia. Oncogene 21 (2002) 8547-8559
8. Deininger M.W.N., Goldman J.M., and Melo J.V. The molecular biology of chronic myeloid leukaemia. Blood 96 (2000) 3343-3356
9. Barnes D.J., Schultheis B., Adedeji S., and Melo J.V. Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. Oncogene 24 (2005) 6432-6440
10. 2+-calmodulin-dependent protein kinase II. Mol. Cell Biol. 20 (2000) 8103-8111
11. Takenoshita S., Mogi A., Nagashima M., Yang K., Yagi K., Hanyu A., Nagamachi Y., Miyazono K., and Hagiwara K. Characterization of the MADH2/Smad2 gene, a human Mad homolog responsible for the transforming growth factor-beta and activin signal transduction pathway. Genomics 48 (1998) 1-11
12. Lee J.Y., Elmer H.L., Ross K.R., and Kelley T.J. Isoprenoid-mediated control of SMAD3 expression in a cultured model of cystic fibrosis epithelial cells. Am. J. Respir. Cell Mol. Biol. 31 (2004) 234-240
13. Tipping A.J., Deininger M.W., Goldman J.M., and Melo J.V. Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. Exp. Hematol. 31 (2003) 1073-1080
14. Fukada T., and Tonks N.K. The reciprocal role of Egr-1 and Sp family proteins in regulation of the PTP1B promoter in response to the p210 Bcr-Abl oncoprotein-tyrosine kinase. J. Biol. Chem. 276 (2001) 25512-25519
15. Kitamura T., Tange T., Terasawa T., Chiba S., Kuwaki T., Miyagawa K., Piao Y.F., Miyazono K., Urabe A., and Takaku F. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J. Cell Physiol. 140 (1989) 323-334
16. Uchida M., Watanabe T., Kunitama M., Mori M., Kikuchi S., Yoshida K., Kirito K., Nagai T., Ozawa K., and Komatsu N. Erythropoietin overcomes imatinib-induced apoptosis and induces erythroid differentiation in TF-1/bcr-abl cells. Stem Cells 22 (2004) 609-616
17. Holtz M.S., Slovak M.L., Zhang F., Sawyers C.L., Forman S.J., and Bhatia R. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 99 (2002) 3792-3800
18. Graham S.M., Jorgensen H.G., Allan E., Pearson C., Alcorn M.J., Richmond L., and Holyoake T.L. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99 (2002) 319-325
19. Le Bousse-Kerdiles M.C., Chevillard S., Charpentier A., Romquin N., Clay D., Smadja-Joffe F., Praloran V., Dupriez B., Demory J.L., Jasmin C., and Martyre M.C. Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood 88 (1996) 4534-4546
20. DeCoteau J.F., Knaus P.I., Yankelev H., Reis M.D., Lowsky R., Lodish H.F., and Kadin M.E. Loss of functional cell surface transforming growth factor beta (TGF-beta) type 1 receptor correlates with insensitivity to TGF-beta in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 94 (1997) 5877-5881
21. Elrick L.J., Jorgensen H.G., Mountford J.C., and Holyoake T.L. Punish the parent not the progeny. Blood 105 (2005) 1862-1866
22. Kretzschmar M., Doody J., and Massague J. Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smadl. Nature 389 (1997) 618-622
23. Hayashida T., Decaestecker M., and Schnaper H.W. Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses in human mesangial cells. FASEB J. 17 (2003) 1576-1578
24. Hanafusa H., Ninomiya-Tsuji J., Masuyama N., Nishita M., Fujisawa J., Shibuya H., Matsumoto K., and Nishida E. Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-beta-induced gene expression. J. Biol. Chem. 274 (1999) 27161-27167
25. Mori S., Matsuzaki K., Yoshida K., Furukawa F., Tahashi Y., Yamagata H., Sekimoto G., Seki T., Matsui H., Nishizawa M., Fujisawa J., and Okazaki K. TGF-beta and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions. Oncogene 23 (2004) 7416-7429
26. Atfi A., Abecassis L., and Bourgeade M.F. Bcr-Abl activates the AKT/Fox O3 signalling pathway to restrict transforming growth factor-beta-mediated cytostatic signals. EMBO Rep. 6 (2005) 985-991
27. Roeder I., Horn M., Glauche I., Hochhaus A., Mueller M.C., and Loeffler M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat. Med. 12 (2006) 1181-1184